Table 2 Hematologic, renal, and cardiac response and progression rates.

From: Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis

 

Old criteria (per protocol)

New criteria

Hematologic

N

92

92

 Responders

48 (52%)

57 (62%)

  CR

6

15

  VGPR

12

22

  PR

30

20

Renal

N

62

62

 Responders

15 (24%)

31 (50%)

   Time to response, median (range)

161 days (28–502)

62 days (28–480)

 Progression

14 (23%)

27 (44%)

   Time to progression, median (range)

196 days (21–1022)

144 days (26–1230)

Cardiac

N

71

71

 Responders

11 (15%)

6 (8%)

   Time to response, median (range)

213 days (58–995)

196 days (35–510)

 Progression

10 (14%)

19 (25%)

   Time to progression, median (range)

232 days (84–697)

30 days (23–396)